Cytotoxic Therapies: Drug Launches in Rare Indications to Offset Sales Decline

Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster products are due to undergo patent expiry and the loss of their branded sales will negatively impact the growth of this market. However, the launch of a number of drugs in rare indications will stabilize growth and offset its decline from generic entry.

Scope

• In-depth analysis of the current and future cytotoxic therapies market across the US, five major European countries and Japan, plus a rest of world snapshot.
• Cytotoxic therapy sales forecasts for brands and generics from 2009 to 2019.
• Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
• Strategies of the leading companies in the cytotoxics market

Contains 114 pages and 47 tables